S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSEAMERICAN:TOVX

Theriva Biologics (TOVX) Stock Price, News & Analysis

$0.47
-0.02 (-4.09%)
(As of 03/28/2024 ET)
Today's Range
$0.44
$0.49
50-Day Range
N/A
52-Week Range
$0.20
$1.20
Volume
42,268 shs
Average Volume
102,955 shs
Market Capitalization
$8.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TOVX stock logo

About Theriva Biologics Stock (NYSEAMERICAN:TOVX)

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

TOVX Stock Price History

TOVX Stock News Headlines

Q4 2023 Theriva Biologics Inc Earnings Call
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Preview: Theriva Biologics's Earnings
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Q3 2023 Theriva Biologics Inc Earnings Call
Theriva Biologics Q3 2023 Earnings Preview
Earnings Outlook For Theriva Biologics
Theriva Biologics Inc TOVX
Samsung Biologics Co. Ltd.
See More Headlines
Receive TOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/25/2024
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:TOVX
CIK
N/A
Employees
21
Year Founded
N/A

Profitability

Net Income
$-19,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.27 per share

Miscellaneous

Free Float
16,145,000
Market Cap
$8.04 million
Optionable
Not Optionable
Beta
1.45
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Steven A. Shallcross CPA (Age 63)
    CEO, CFO, Treasurer, Corporate Secretary & Director
    Comp: $997.67k
  • Dr. Vince Wacher Ph.D.
    Head of Product & Corporate Development
  • Dr. Michael Kaleko M.D.
    Ph.D., Senior Vice President of Research & Development
  • Dr. Ramon Alemany Ph.D.
    Senior VP of Discovery & Chairman of Scientific Advisory Board
  • Ms. Lara M. Guzman
    Senior Director of Project Operations

TOVX Stock Analysis - Frequently Asked Questions

Who are Theriva Biologics' major shareholders?

Theriva Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.15%), Vanguard Group Inc. (2.15%) and Citadel Advisors LLC (0.34%).
View institutional ownership trends
.

How do I buy shares of Theriva Biologics?

Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:TOVX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners